Last reviewed · How we verify
NCT04944953
To Compare the Safety and Efficacy of "HG-102" With Botox® in the Improvement of Moderate to Severe Glabellar Lines.
Phase 1 trial testing Botulinum Toxin Type A Injection [Botox] in Glabellar Lines in 38 participants. Completed in 16 December 2021.
2 September 2021
Quick facts
| Lead sponsor | Hugel |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 38 |
| Start date | 11 June 2021 |
| Primary completion | 2 September 2021 |
| Estimated completion | 16 December 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Botulinum Toxin Type A Injection [Botox] — full drug profile →
- Botulinum toxin type A injection [HG-102] — full drug profile →
Conditions studied
- Glabellar Lines — all drugs for Glabellar Lines →
Sponsor
Hugel — full company profile →
Who can join
Adults 19 to 65, any sex, with Glabellar Lines. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare the safety and efficacy of "HG-102" with Botox® in the improvement of moderate to severe glabellar lines.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04944953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Botulinum Toxin Type A Injection [Botox]
Trials testing the same drug.
- NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis · Phase 4 · not yet recruiting
- NCT04695600 — Onabotulinum Toxin A (Botox) in the Treatment of Transfer Dysphagia · Phase 2, PHASE3 · unknown
- NCT06282679 — Clinical Observation of Botulinum Toxin A Treatment in the Treatment of Rosacea · NA · unknown
- NCT05072821 — Botulinum Toxin Type a Injection to Prevent Keloid Recurrence · Phase 4 · completed
- NCT04171258 — Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia · Phase 1 · completed
Other recruiting trials for Glabellar Lines
Currently open trials in the same condition.
- NCT06205797 — To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) · Phase 3 · recruiting
Other Hugel trials
Trials by the same sponsor.
- NCT06216418 — Evaluate the Safety and Efficacy of 'BRFS-18G-S100WH' as Compared to 'MINT Lift FINE+' in Subject With Nasolabial Folds · NA · unknown
- NCT04443244 — Evaluate the Safety and Efficacy of Botulax® in Subjects With Benign Masseteric Hypertrophy · Phase 2 · completed
- NCT04171258 — Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia · Phase 1 · completed
- NCT04186442 — Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder · Phase 1 · completed
- NCT04012099 — the Hypertrophic Scar Prevention of BMT101. · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04944953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hugel
- Last refreshed: 24 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04944953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing